OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.24 Million Stock Holdings in Afya Limited (NASDAQ:AFYA)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Afya Limited (NASDAQ:AFYA) by 27.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 77,815 shares of the company’s stock after buying an additional 16,918 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Afya were worth $1,236,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Lifestyle Asset Management Inc. grew its stake in shares of Afya by 5.5% in the fourth quarter. Lifestyle Asset Management Inc. now owns 17,682 shares of the company’s stock valued at $281,000 after acquiring an additional 929 shares in the last quarter. Blue Trust Inc. boosted its holdings in Afya by 296.9% in the 4th quarter. Blue Trust Inc. now owns 2,072 shares of the company’s stock valued at $35,000 after purchasing an additional 1,550 shares during the period. Jane Street Group LLC boosted its holdings in Afya by 3.7% in the 4th quarter. Jane Street Group LLC now owns 56,341 shares of the company’s stock valued at $895,000 after purchasing an additional 2,032 shares during the period. Dodge & Cox grew its position in shares of Afya by 7.1% during the 4th quarter. Dodge & Cox now owns 31,262 shares of the company’s stock worth $496,000 after purchasing an additional 2,079 shares in the last quarter. Finally, Van ECK Associates Corp increased its holdings in shares of Afya by 41.9% during the fourth quarter. Van ECK Associates Corp now owns 9,677 shares of the company’s stock worth $154,000 after purchasing an additional 2,856 shares during the period. Institutional investors and hedge funds own 88.02% of the company’s stock.

Afya Stock Performance

Shares of NASDAQ:AFYA opened at $19.22 on Wednesday. Afya Limited has a 1 year low of $14.52 and a 1 year high of $20.06. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of 15.50, a price-to-earnings-growth ratio of 0.29 and a beta of 0.60. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.60 and a quick ratio of 1.60. The company’s 50 day simple moving average is $18.05 and its 200 day simple moving average is $16.95.

Afya Announces Dividend

The firm also recently declared a — dividend, which was paid on Friday, April 4th. Stockholders of record on Wednesday, March 26th were paid a $0.232 dividend. The ex-dividend date of this dividend was Wednesday, March 26th. Afya’s payout ratio is 17.69%.

Analyst Ratings Changes

A number of research firms have commented on AFYA. JPMorgan Chase & Co. lowered their price objective on Afya from $25.00 to $20.50 and set a “neutral” rating on the stock in a research note on Friday, January 17th. Citigroup restated a “sell” rating and issued a $15.00 price target (down previously from $18.00) on shares of Afya in a research report on Friday, January 31st. Finally, Morgan Stanley cut shares of Afya from an “equal weight” rating to an “underweight” rating and cut their price objective for the stock from $19.00 to $17.00 in a research report on Tuesday, March 11th. Three equities research analysts have rated the stock with a sell rating and two have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $17.60.

Afya Company Profile

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.